NICE Approves Opdivo Use in Hodgkin Lymphoma

The UK Institute of Health and Care Excellence approved the use of Opdivo (nivolumab) for routine use in patients with classical Hodgkin lymphoma who have exhausted all other treatments.

Bristol-Myers Squibb’s immunotherapy will be used for patients whose cancer is progressing despite a stem cell transplant from their own cells and Adcetris treatment (brentuximab vedotin). In a small proportion of these patients, Opdivo could allow them to undergo a stem cell transplant from a healthy donor, NICE said.

BMS estimated that around 30 patients could benefit from Opdivo in this setting in the first year.